VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TTRXTurn Therapeutics Inc.
$5.77$172M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTTRXEarnings History

TTRX logoTurn Therapeutics Inc. (TTRX) Earnings History

Net Loss

3 years of earnings data (2023–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$4M
● Net Loss
TTM EPS (Diluted)
$-0.13
Per share, diluted
YoY EPS Growth
-76.9%
Declining
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-141.7%
Return on Assets-45.0%
Record Annual Net Income-$2MFY2024
Record Quarterly EPS$0.01Q4 2025
Consecutive Profitable Years0years
Q1 2026
Net Income-$970,972
EPS (Diluted)$-0.03
YoY Growth-76.9%Declining
QoQ Growth-447.9%Declining

Loading earnings history...

Turn Therapeutics Inc. (TTRX) Earnings Overview

As of June 23, 2026, Turn Therapeutics Inc. (TTRX) reported trailing twelve-month net income of -$4M, reflecting -76.9% year-over-year growth. The company earned $-0.13 per diluted share over the past four quarters.

Looking at the long-term picture, TTRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2024.

Turn Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including RCUS (-$369M net income, -142.9% margin), IMVT (-$506M net income), ARQT (-$2M net income, -4.3% margin), TTRX has comparable earnings metrics. Compare TTRX vs RCUS →

TTRX Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
TTRX logoTTRXCurrent
-$4M$-0.13--141.7%-76.9%—
RCUS logoRCUS
-$369M$-2.94-142.9%-63.3%-4.8%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
ARQT logoARQT
-$2M$-0.02-4.3%-9.3%+88.8%
KYMR logoKYMR
-$315M$-3.23-794.4%-25.8%-23.8%
PRAX logoPRAX
-$327M$-11.31--45.8%-32.0%
Best in group
Lowest in group

TTRX Historical Earnings Data (2023–2025)

3 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$3M-80.6%-$6M$-0.23--
2024-$2M+22.9%-$2M$-0.13--
2023-$2M--$2M$-0.17--

Download Data

Export TTRX earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

3+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TTRX — Frequently Asked Questions

Quick answers to the most common questions about buying TTRX stock.

What is TTRX earnings per share (EPS)?

TTRX trailing twelve-month (TTM) diluted EPS is $-0.13, reflecting -76.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2023 to 2025 is available in the table on this page.

What is Turn Therapeutics Inc.'s net income?

Turn Therapeutics Inc. (TTRX) trailing twelve-month net income is $-4M as of 2025. Earnings declined -76.9% year-over-year.

Is TTRX profitable?

TTRX is not currently profitable on a TTM basis, reporting a net loss of $-4M. Net margin is N/A. Investors should monitor for a return to profitability.

What is TTRX's earnings growth rate?

TTRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2023 to 2025.

What are TTRX's profit margins?

Turn Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -141.7%.

Is TTRX growing earnings?

TTRX earnings are declining — EPS fell -76.9% year-over-year. TTM net income dropped to $-4M. This contrasts with the 5-year CAGR of N/A.

What was TTRX's best earnings year?

Turn Therapeutics Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2024. Earnings history on this page spans 2023 to 2025 and includes all annual and quarterly figures.

What were TTRX's earnings last quarter?

TTRX's most recent reported quarter was Q1 2026. Net income was $-970972.00 with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.

TTRX Earnings Over Time (2023–2025)

Net income & EPS — annual and quarterly view